An observational study in Acute Bacterial Sinusitis, sponsored by Bayer. Completed at 19 sites in 19 countries. Per ClinicalTrials.gov, last updated 2012-11-20.
Sponsored by Bayer · Observational
For each patient, an initial visit and at least one follow-up visit at the end of treatment should be documented by the treating physician in the case report form.
Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
Exclusion Criteria:
Drug: Avelox (Moxifloxacin, BAY12-8039)
Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
Evaluation of potential benefits of an antibacterial therapy with Avelox® (moxifloxacin) in patients with acute bacterial sinusitis to whom this treatment was prescribed. Especially the time to improvement and resolution of clinical signs and symptoms of
Time frame: Documentation at baseline and at at least one follow-up visit. Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).
Evaluation of tolerability and safety of Avalox® in daily practice were investigated.
Time frame: Evaluation of therapy outcome at last follow-up visit at end of therapy (approximately after 7 days).
Patient characteristics in acute bacterial sinusitis
Time frame: Documentation at baseline visit.
History and frequency of sinusitis episodes
Time frame: Documentation at baseline visit.
Diagnostic procedures and therapeutic options chosen by physicians in daily practice
Time frame: Documentation at baseline visit.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bayer